Only Two Ring Sulfurs In The Hetero Ring Patents (Class 514/440)
  • Publication number: 20130071372
    Abstract: Metallo-proteins including but not limited to lactoferrin (LF), transferrin (TF) and ovotransferrin (OTF) (all members of transferrin family), ceruloplasmin (CP) and metallo-thionein (MT) were found to stabilize and enhance the bio-functional activity of tocotrienol (T3), T3 mixtures or derivates. The synergism between MP and T3 also promote the intestinal transfer and the ultimate bio-availability of T3 and T3-derivatives for physiological functions. Such functional synergism includes hypocholesterolemic, anti-thrombotic, antioxidant, anti-athermogenic, anti-inflammatory and immuno-regulatory activities of T3 agents. Addition of a non-protein-type metal chelator provided further improvement in the action of the bio-functional activity of T3. These T3 compositions are useful as pharmaceuticals, in cosmetics, in foods and as nutritional supplements.
    Type: Application
    Filed: November 9, 2012
    Publication date: March 21, 2013
    Applicant: Naidu LP
    Inventor: Naidu LP
  • Publication number: 20130065909
    Abstract: The invention relates to Fatty Acid Fumarate Derivatives; compositions comprising an effective amount of a Fatty Acid Fumarate Derivative; and methods for treating or preventing cancer, a metabolic disorder or neurodegenerative disorder comprising the administration of an effective amount of a Fatty Acid Fumarate Derivative.
    Type: Application
    Filed: November 9, 2012
    Publication date: March 14, 2013
    Applicant: CATABASIS PHARMACEUTICALS, INC.
    Inventors: Jill C. Milne, Michael R. Jirousek, Jean E. Bemis, Chi B. Vu
  • Publication number: 20130058878
    Abstract: Geranylgeranyl-2-propanol compound (GGP) having the following formula (I) is proposed for use according to the present invention as a cosmetic active compound for the prevention and treatment of aging of skin and its appendages. The GGP has a protective action against oxidative stress and free radical, on telomeres and on mitochondria and its activity. In particular, GGP can be used for the treatment of wrinkles, fine lines and visible discontinuities of skin, for the treatment pigmentation disorders.
    Type: Application
    Filed: April 7, 2011
    Publication date: March 7, 2013
    Applicant: SEDERMA
    Inventors: Arnaud Fournial, Philippe Mondon, Olivier Peschard
  • Publication number: 20130045273
    Abstract: Methods for using nutritional supplements containing lipoic acids and sulfur containing compounds to maintain or increase the levels of cellular GSH in the body are described. In some instances, the nutritional supplements can increase both the levels of GSH, vitamin C, GST activity, and antioxidant protection in the blood. The nutritional supplement contain a first part containing an effective amount of a lipoic acid and a second part containing an effective amount of a sulfur containing compound that increases the level of GSH vitamin C, GST activity, and antioxidant protection in the blood The first part and second part of the nutritional supplement can be partially or completely separated. The increased GSH and vitamin C levels increases the detoxification ability of the body as measured by the GST (Glutathione S-Transferases) activity and the antioxidant protection as measured by SAR (Serum Antioxidant Reserve). Other embodiments are described.
    Type: Application
    Filed: August 19, 2011
    Publication date: February 21, 2013
    Inventors: John Cuomo, Mark J. Brown, Brian M. Dixon, Christine Dern
  • Publication number: 20130041020
    Abstract: The invention relates to methods of control and prophylaxis of inflammation and mitigation of inflammatory conditions, particularly arthritis and joint pain, in companion animals, e.g., dogs or cats, comprising administering a diet comprising lipoic acid.
    Type: Application
    Filed: May 9, 2011
    Publication date: February 14, 2013
    Applicant: Hill's Pet Nutrition, Inc.
    Inventor: Nolan Zebulon Frantz
  • Patent number: 8367716
    Abstract: The present invention relates to the use of the cyclic dinucleotide c-di-GMP and cyclic dinucleotide analogues thereof in a method for attenuating virulence of a microbial pathogen or for inhibiting or reducing colonization by a microbial pathogen. This method further inhibits microbial biofilm formation and is capable of treating bacterial infections. The microbial colonization or biofilm formation inhibited or reduced may be on the skin or on nasal or mucosal surface. The microbial colonization or biofilm formation inhibited can also be on the surfaces of medical devices, especially those in close contact with the patient, as well on the surfaces of industrial and construction material where microbial colonization and biofilm formation is of concern.
    Type: Grant
    Filed: July 22, 2004
    Date of Patent: February 5, 2013
    Inventor: David K. R. Karaolis
  • Publication number: 20130011488
    Abstract: A method and compositions for treating cancer is described using at least two epigenetic modifiers. In various embodiments, hyperbaric oxygen therapy and glycolytic inhibition therapy are used as well.
    Type: Application
    Filed: July 6, 2012
    Publication date: January 10, 2013
    Inventor: Mohammad Nezami MD
  • Publication number: 20130005712
    Abstract: The present invention relates to a composition for noxious organisms-controlling agent having a synergistic effect and a method for using said composition, which comprises, as active ingredients thereof, one or more compounds selected from the phthalamide derivatives represented by general formula (I) being useful as an insecticide or acaricide and one or more compounds selected from the compounds having insecticidal, acaricidal or nematocidal activity: wherein R1, R2 and R3 may be the same or different and each represent hydrogen atom, C3-C6 cycloalkyl, -A1--Qp, etc., each of X and Y may be the same or different and represents hydrogen atom, halogen atom, etc., n is an integer of 1 to 4, m is an integer of 1 to 5, and each of Z1 and Z2 represents O or S.
    Type: Application
    Filed: September 11, 2012
    Publication date: January 3, 2013
    Inventors: Kazuyuki Sakata, Masayuki Morimoto, Hiroshi Kodama, Tetsuyosi Nishimatsu
  • Publication number: 20120328588
    Abstract: A compound preparation contains alpha-lipoic acid and nimodipine at a ratio from 5:1 to 40:1. The above-mentioned compound preparation can be used for the prevention and treatment of noise-induced hearing impairment. This compound preparation not only increases the efficacy but decreases the dosage of nimodipine, reduces the side effects and improves the patient compliance.
    Type: Application
    Filed: May 8, 2011
    Publication date: December 27, 2012
    Applicant: The Second Military Medical University of Chinese PLA
    Inventors: Shen Gao, Jing Gao, Quangang Zhu, Xiying Wang, Xueying Ding, Wei Zhang, Xiaoyu Wang, Min Zhang, Xin Wu, Lihua Ye
  • Publication number: 20120328695
    Abstract: Pharmaceutical compositions and methods for the treatment of chronic fatigue in human patients comprising a central nervous system (CNS) stimulant in a daily low-dosage amount in combination with therapeutically effective daily amounts of micronutrients, comprising acetyl L-carnitine, L-tyrosine, N-acetyl cysteine, and alpha-lipoic acid. The CNS and micronutrient components may be in an oral dosage composition containing a low dosage amount of CNS stimulant such as about 2.5 mg methylphenidate HCl together with about 60-250 mg acetyl L-carnitine, 50-200 mg L-tyrosine, 60-250 mg N-acetyl cysteine, and 25-100 mg alpha-lipoic acid.
    Type: Application
    Filed: June 22, 2012
    Publication date: December 27, 2012
    Inventor: Jon D. Kaiser
  • Publication number: 20120321603
    Abstract: A composition and treatment method are disclosed for one or more of alpha, beta, and gamma-Cyclodextrin and a natural molecule or fragment thereof wherein the natural molecule is sometimes Glutathione, is non-acetylated, non-Esterified, and non-fatty acid attached, and the composition is administered parenterally and non-interveneously.
    Type: Application
    Filed: June 18, 2012
    Publication date: December 20, 2012
    Inventors: Nayan Patel, Chinh Tran
  • Publication number: 20120316157
    Abstract: The present invention provides a composition having an excellent controlling activity on plant disease. The composition comprising the compound represented by the formula (1) and one or more heterocyclic fungicidal compound selected from the group (A) shows an excellent controlling activity on a plant disease.
    Type: Application
    Filed: March 2, 2011
    Publication date: December 13, 2012
    Applicant: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: So Kiguchi, Soichi Tanaka, Mayuko Ozawa, Atsushi Iwata
  • Publication number: 20120288488
    Abstract: Compositions and methods for preventing or controlling bacteria, viruses and parasitic growths that cause diarrhea, pneumonia and septicemia in animals comprising a biocidal system comprised of a primary biocide and a pH buffer component; a cationic or ionic surfactant having an HLB of from about 5 to about 30; a thickening agent; and an aqueous based carrier.
    Type: Application
    Filed: January 9, 2012
    Publication date: November 15, 2012
    Applicant: NOBLE ION, LLC
    Inventors: Burt R. Sookram, John W. Veenstra
  • Publication number: 20120283320
    Abstract: The present invention relates to oral nutritional and therapeutic products which are useful for preventing or treating compensated and decompensated insulin resistance and associated diseases and sequelae, or diabetes mellitus and its sequelae, complications, and co-morbidities, comprising magnesium R-(+)-alpha-lipoate.
    Type: Application
    Filed: July 13, 2012
    Publication date: November 8, 2012
    Applicant: BIOLINK LIFE SCIENCES, INC.
    Inventor: Deanna J. Nelson
  • Publication number: 20120277294
    Abstract: Novel compounds, and in particular to diacylglycerol (1,3-DAG) and alpha-lipoic acid (LA) and/or dihydro-alpha-lipoic acid (DHLA) derivatives. In particular these novel compounds are used as functional food additives. These may for example be used as nutraceuticals and/or pharmaceuticals in the prevention and treatment of obesity, diabetes, atherosclerosis, oxidative stress and other lifestyle-related diseases.
    Type: Application
    Filed: December 23, 2010
    Publication date: November 1, 2012
    Inventor: Paresh Dutta
  • Patent number: 8278358
    Abstract: The invention describes alpha lipoic acid complexes, that can be oligomeric, polymeric, monomeric and mixtures thereof. The complexes can be salts, chelates, etc. of the oligomers, polymers, or monomeric alpha lipoic acid.
    Type: Grant
    Filed: July 2, 2007
    Date of Patent: October 2, 2012
    Assignee: Omnica GmbH
    Inventor: Thomas Eidenberger
  • Publication number: 20120245540
    Abstract: According to an illustrative embodiment a method to promote healing of a wound is provided comprising contacting the wound with a biologically active composition comprising a lipoic acid derivative and gelatin. In another embodiment a topical composition is provided, which can be formulated as a homogenous mixture, such as a spray, mist, aerosol, lotion, cream, solution, oil, gel, ointment, paste, emulsion or suspension or applied on a carrier material, such as a bandage, gauze, foam, sponge, hydrogel, hydrocolloid, hydrofiber, occlusive dressing, adhesive composition or scaffold. Methods for producing such a topical composition and carrier material with the topical composition applied thereto are also disclosed.
    Type: Application
    Filed: March 24, 2011
    Publication date: September 27, 2012
    Inventors: Dmitry Zimnitsky, Jenny Finkbiner
  • Patent number: 8263639
    Abstract: Disclosed herein are the compounds shown below and methods of their synthesis. The value m is a positive integer. R comprises an alkyl chain or an alkoxy chain. Each X comprises a metal binding group. Each E is a methoxy group or comprises a biomolecule reactive group or a residue thereof. E optionally comprises a protecting group. The value n is a positive integer. The value p is zero or one. Y is OCH3, OH, NH2, or COOH.
    Type: Grant
    Filed: April 21, 2010
    Date of Patent: September 11, 2012
    Assignee: The United States of America, as represented by the Secretary of the Navy
    Inventors: Michael Stewart, Kimihiro Susumu, Bing C. Mei, Hedi M Mattoussi
  • Publication number: 20120207707
    Abstract: Methods of increasing production, stability or activity of a target polypeptide are provided herein. The method includes increasing the level of an antioxidant in a cell comprising a polynucleotide encoding the target polypeptide. Also provided are cells and transgenic organisms produced using the methods described herein. Methods of treating a subject with a condition treatable by administration of the target polypeptide are also disclosed. Finally methods and compositions for transiently increasing antioxidants in plant cells are provided.
    Type: Application
    Filed: October 22, 2010
    Publication date: August 16, 2012
    Inventors: Maureen C. Dolan, Argelia Lorence, Giuliana Medrano
  • Publication number: 20120189600
    Abstract: The present invention relates to compositions and methods for treating neurodegenerative diseases. In some embodiments, the present invention provides compositions for treating and preventing presbycusis.
    Type: Application
    Filed: March 21, 2012
    Publication date: July 26, 2012
    Applicant: MARINE BIO CO., LTD.
    Inventor: Shinichi Someya
  • Publication number: 20120183621
    Abstract: Non-Small Cell Lung Carcinomas (NSCLCs) are treated with Gel Micro-Particles (GMPs) that passively accumulate in the lungs and contain Nano-Particles (NPs) combining one or more therapeutic agents that are cytotoxic to the NSCLC with one or more NSCLC active targeting ligands, as well as one or more other optional agents that increase cellular uptake, enhance the pro-apoptotic effect of the chemotherapeutic agent(s), and the like. NPs targeting other cancer cells are also disclosed, as well as NP-containing GMPs that reduce the occurrence of tumor metastasis.
    Type: Application
    Filed: November 14, 2011
    Publication date: July 19, 2012
    Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Patrick J. Sinko, Jieming Gao, Manjeet Deshmukh, Xiaoping Zhang, Matthew S. Palombo, Sherif Ibrahim
  • Patent number: 8221799
    Abstract: The invention is directed to a method for administering antioxidant micronutrient formulations comprising multiple dietary and endogenous antioxidants, B-vitamins, vitamin D and minerals at appropriate dosages and dose schedules particularly chosen to produce long-term ‘optimal health’ effects in individuals of various age groups and occupations, with particular emphasis on reducing and/or eliminating acute and/or long term effects of environmental and physical stressors and toxic chemicals to which current Operating Forces and veterans of military service are or have been exposed.
    Type: Grant
    Filed: February 5, 2007
    Date of Patent: July 17, 2012
    Assignee: Premier Micronutrient Corporation
    Inventors: Kedar N. Prasad, Gerald M. Haase, William C. Cole
  • Publication number: 20120172421
    Abstract: The disclosure herein provides a compound of formula 1. The disclosure also provides a method of synthesizing the compound of formula 1. The compound of formula 1 or its pharmaceutical acceptable salts, as well as polymorphs, solvates, and hydrates thereof may be formulated as pharmaceutical composition. The pharmaceutical composition of compound of formula 1 or the final compound may be formulated for non-invasive peroral, topical (example transdermal), enteral, transmucosal, targeted delivery, sustained release delivery, delayed release, pulsed release and parenteral methods. Such compositions may be used to treat chronic pain manifested with chronic diseases or its associated complications. The compound may also be offered as a kit.
    Type: Application
    Filed: March 13, 2012
    Publication date: July 5, 2012
    Applicant: KRISANI BIOSCIENCES (P) LTD
    Inventor: Mahesh Kandula
  • Publication number: 20120157405
    Abstract: A composition for the treatment of “Burning Feet Syndrome” includes pantothenic acid or its analogs, or its derivatives, or its synonyms, alpha-lipoic acid or its analogs, or its derivatives, or its synonyms, and L-arginine or its analogs, or its derivatives, or its synonyms. The composition may also include at least one substance selected from the group consisting of B1, B2, B3, B6, B7, B9, B12, Acetly-L-Carnitine, N-acetlycystein, Omega-3 fatty acids, Omega-6 fatty acids, Vitamin E, and Taurine or any of their analogs, derivatives, or synonyms. The composition is used in a method for the treating of “Burning Feet Syndrome” by administering to a human such a composition.
    Type: Application
    Filed: September 12, 2011
    Publication date: June 21, 2012
    Inventor: John B. White, III
  • Publication number: 20120157515
    Abstract: Disclosed herein Methods and composition for the treatment of an individual with “Burning Feet Syndrome”. Included are the manner and process of making the composition, administration, uses, and effective therapeutic amounts of Pantothenic acid and Alpha-lipoic acid with no adverse side effects. The composition can be used to prophylax (prevent), treat acute or chronic symptoms caused by “Burning Feet Syndrome”. In combination with certain adjuvants, carriers, vehicles and delivery systems to improve the efficacy.
    Type: Application
    Filed: December 19, 2010
    Publication date: June 21, 2012
    Inventor: John Bowman White, III
  • Patent number: 8198317
    Abstract: The present invention provides novel methylenedioxy phenolic compounds and their derivatives, methods of making them and methods of using them to treat or prevent cardiovascular disease, vascular disease and/or inflammatory disease, as well as Type I and Type II Diabetes and Dyslipidemia patients at risk for hypertension, stroke, cardiovascular and renal disease.
    Type: Grant
    Filed: August 5, 2009
    Date of Patent: June 12, 2012
    Assignees: The Ohio State University Research Foundation, Invasc Therapeutic, inc.
    Inventors: Sampath Parthasarathy, Sanjay Rajagopalan, Desikan Rajagopal
  • Publication number: 20120141614
    Abstract: A carotenoid substance called zeaxanthin, when ingested orally at suitable dosages such as 30 to 100 mg/day for a span of 1 to 2 weeks, can provide effective protection against sunburns, and can give skin a darker tint that emulates a healthy suntan. In tests involving adults, it was found that zeaxanthin dosages of 30 to about 80 mg per day were sufficient to induce: (i) a mild but noticeable tinting, shading, or darkening of skin color, comparable to a mild suntan; (ii) a substantial increase in the person's ability to withstand elevated levels of sun or UV exposure; and, (iii) an increased ability of reddened and sunburned skin to convert into intact skin that looks browned and healthily tanned. Oral ingestion of dosages of zeaxanthin after a noticeable darkening of the skin has been achieved further enhances a tanned appearance and/or protects against sun damage.
    Type: Application
    Filed: December 1, 2011
    Publication date: June 7, 2012
    Applicant: ZeaVision LLC
    Inventors: Dennis L. Gierhart, Joseph A. Fox
  • Publication number: 20120115939
    Abstract: The present provides methods for using lipoic acid. In one embodiment, the methods include administering lipoic acid to a female subject in need thereof, wherein at least 10 milligrams lipoic acid per kilogram of body weight is administered. In another embodiment, the methods include administering to a female subject in need thereof an effective amount of lipoic acid, wherein concentration of progesterone in the blood of the subject is increased compared to the subject prior to administration of the lipoic acid. The subject may be pregnant.
    Type: Application
    Filed: November 9, 2011
    Publication date: May 10, 2012
    Applicant: NDSU Research Foundation
    Inventors: Kimberly Ann Vonnahme, Erika Lynn Berg
  • Patent number: 8168241
    Abstract: A dietary supplement for enhancing physical performance of human subjects is disclosed. The supplement in dry, finely-divided form includes as a major ingredient a soy protein isolate containing at least 80% protein on a moisture-free basis with lesser amounts of carbohydrate, free form amino acids, medium chain triglycerides, creatine monohydrate, l-carnitine, grape seed extract, coenzyme Q10, piper nigrum extract, and alpha lipoic acid. In a preferred embodiment, the supplement also includes minor amounts of conjugated linoleic acid and phosphatidylserine/phosphatidylcholine complex.
    Type: Grant
    Filed: February 18, 2004
    Date of Patent: May 1, 2012
    Assignee: Reliv International, Inc.
    Inventors: Carl W. Hastings, David J. Barnes, Christine A. Daley
  • Publication number: 20120093940
    Abstract: A medical food and/or nutritional supplement for oral administration by mammals includes ?-lipoic acid, linolenic acid complex, biotin, and coenzyme Q-10. A preferred method of manufacturing the medical food or nutritional supplement is by separate microencapsulation of one or more of the components followed by encapsulation of the individual components, for oral administration. Other methods of delivery include packaging in impermeable, disposable packets and mixing the formulations with food or a cold liquid.
    Type: Application
    Filed: April 11, 2011
    Publication date: April 19, 2012
    Applicant: RESPONSE SCIENTIFIC, INC.
    Inventors: Gregory D. Webster, Emmanuel C. Opara
  • Patent number: 8153685
    Abstract: The present invention provides new salts and/or addition compounds and/or complex compounds of guanidinoacetic acid with malic acid, aspartic acid, ascorbic acid, succinic acid, pyruvic acid, fumaric acid, gluconic acid, ?-ketoglutaric acid, oxalic acid, pyroglutamic acid, 3-nicotinic acid, lactic acid, citric acid, maleic acid, sulfuric acid, acetic acid, formic acid, 2-hydroxybenzoic acid, L-carnitine, acetyl-L-carnitine, taurine, betaine, choline, methionine and lipoic acid as well as in the form of sodium, potassium or calcium guanidinoacetate. These salts have improved physiological and therapeutic properties and are particularly suitable for use as dietary supplements, as animal feeds and in cosmetic or dermatological preparations in which especially the marked stability and good bioavailability of the salts come to the fore.
    Type: Grant
    Filed: March 2, 2006
    Date of Patent: April 10, 2012
    Assignee: Alzchem Trostberg GmbH
    Inventors: Thomas Gastner, Hans-Peter Krimmer
  • Publication number: 20120076842
    Abstract: The present invention concerns a new cosmetic use of Tyr-Arg dipeptide to stimulate molecules of the extracellular matrix in order to prevent and treat cutaneaous sagging, in particular due to natural gravity. The invention is useful in the preparation of tightening, finning, contouring, and lifting cosmetic products.
    Type: Application
    Filed: May 25, 2010
    Publication date: March 29, 2012
    Applicant: SEDERMA
    Inventors: Arnaud Fournial, Philippe Mondon
  • Patent number: 8137925
    Abstract: The invention provides compositions and methods of use thereof for labeling peptide and proteins in vitro or in vivo. The methods described herein employ lipoic acid ligase or mutants thereof, and lipoic acid analogs recognized by lipoic acid ligase and lipoic acid ligase mutants.
    Type: Grant
    Filed: November 9, 2007
    Date of Patent: March 20, 2012
    Assignee: Massachusetts Institute of Technology
    Inventors: Alice Y. Ting, Marta Fernandez Suarez, Hemanta Baruah
  • Publication number: 20120052126
    Abstract: Nanoemulsions contain particles that comprise an outer shell layer containing at least one oil and a core portion containing at least one antioxidant and, optionally, other health-promoting compounds, wherein the nanoemulsions are relatively stable for prolonged periods without significant change in physical properties and are suitable for administering to humans and other mammals orally, topically, intravenously, transdermally, and subcutaneously.
    Type: Application
    Filed: August 29, 2011
    Publication date: March 1, 2012
    Inventors: Yashwant Pathak, Hieu T. Tran
  • Publication number: 20120052051
    Abstract: The method of treating diabetes-related vascular complications includes the treatment of diabetic patients with ?-lipoic acid (LA) in order to mitigate the negative impact of diabetes-related vascular dysfunctions upon vascular homeostasis. The treatment method includes the step of administering to the patient an initial dosage of ?-lipoic acid believed to be therapeutically effective. The patient's response is then monitored by measuring ?-lipoic acid-responsive biomarkers and by performing assays from blood and tissue taken from the patient.
    Type: Application
    Filed: August 15, 2011
    Publication date: March 1, 2012
    Applicant: KUWAIT UNIVERSITY
    Inventors: FAHD AL-MULLA, MILAD BITAR
  • Publication number: 20120039796
    Abstract: A bio compatible free radical suspension, comprising of oxygen and electronically modified reaction intermediates, where a fluorocarbon is used as an inert medium for stabilization of reaction intermediates. A stabilized bio compatible electronically modified derivative suspension is produced by the subjecting a fluorocarbon to certain stressors, such as oxidizing agents, reactive intermediates, physiological gases, benzo-?-pyrone derivatives, ultrasonic-cavitation, electric fields, magnetic fields, UV radiation, active metal catalyst, surfactant reactants, buffers, electrolytes, glucose, glucose derivatives, for the purpose of inducing a cascading immune response.
    Type: Application
    Filed: August 13, 2011
    Publication date: February 16, 2012
    Inventor: Demetrios Markou
  • Publication number: 20120035250
    Abstract: Described herein are routes of synthesis and therapeutic uses of 1-alkyl, 2-acyl glycerol derivatives of formula I: which when administered to mammalian biological systems result in increased cellular concentrations of specific sn-2 substituted ethanolamine plasmalogens independent of the ether lipid synthesis capacity of the system. Elevating levels of the specific sn-2 substituted species in this way can cause lowering of membrane cholesterol levels and the lowering of amyloid secretion. These compounds can be used for the treatment or prevention of diseases of aging associated with increased membrane cholesterol, increased amyloid, and decreased plasmalogen levels, such as neurodegeneration (including Alzheimer's disease, Parkinson's disease and age-related macular degeneration), cognitive impairment, dementia, cancer (e.g. prostate, lung, breast, ovarian, and kidney cancers), osteoporosis, bipolar disorder and vascular diseases (such as atherosclerosis, hypercholesterolemia).
    Type: Application
    Filed: December 18, 2009
    Publication date: February 9, 2012
    Applicant: PHENOMENOME DISCOVERIES INC.
    Inventors: M. Amin Khan, Paul L. Wood, Dayan Goodenowe, Rishikesh Mankidy, Pearson Ahiahonu
  • Publication number: 20120022147
    Abstract: The disclosure herein provides a composition compound of formula 1. The disclosure also provides a method of synthesizing the compound of formula 1. The compound of formula 1 or its pharmaceutical acceptable salts, as well as polymorphs, solvates, and hydrates thereof may be formulated as pharmaceutical composition to be used for treatment of pain. The pharmaceutical composition of compound of formula 1 or the final compound may be formulated for non-invasive peroral, topical (example transdermal), enteral, transmucosal, targeted delivery, sustained release delivery, delayed release, pulsed release and parenteral methods. Such compositions may be used to treat chronic pain manifested with chronic diseases or its associated complications. The compound of formula 1 may also be offered as a kit.
    Type: Application
    Filed: September 9, 2011
    Publication date: January 26, 2012
    Applicant: KRISANI BIOSCIENCES (P) LTD
    Inventor: Mahesh Kandula
  • Publication number: 20120004291
    Abstract: The invention encompasses pet food compositions and methods for the treatment and/or prevention of diseases or disorders in companion animals, for example, for the treatment or obesity, including administering a pet food composition including pyruvic acid or a salt thereof to a companion animal, or lipoic acid or salt thereof and pyruvic acid or a salt thereof to a companion animal. The invention encompasses pet food compositions and methods for managing weight including administering a pet food composition including pyruvic acid or a salt thereof, or lipoic acid or a salt thereof and pyruvic acid or a salt thereof to a companion animal to a companion animal.
    Type: Application
    Filed: January 15, 2010
    Publication date: January 5, 2012
    Inventors: Ryan Michael Yamka, Nolan Zebulon Frantz, Steven C. Zicker
  • Publication number: 20110318321
    Abstract: The present invention relates to a controlled release pharmaceutical or food formulation comprising at least one active pharmaceutical or food ingredient dispersed in a mixture of a glycogen with a polysaccharide, and the process for its preparation. The invention also relates to a slow release system represented by a mixture of a glycogen with a polysaccharide, and its use for the preparation of slow release pharmaceutical or food formulations.
    Type: Application
    Filed: January 8, 2010
    Publication date: December 29, 2011
    Applicant: AZIENDE CHIM.RIUN.ANG.FRANC.A.C.R.A.F. S.p.A.
    Inventors: Stefano Selva, Leonardo Marchitto, Giovanni Battista Ciottoli, Lorella Ragni, Vincenzo Russo, Elisa Liberati
  • Publication number: 20110301180
    Abstract: It has been discovered that inhibiting mitochondrial respiration in platelets reduces platelet activation or platelet aggregation. Certain heterocyclic compounds significantly reduced one or more platelet functions including clumping, sticking or platelet-stimulated clotting. Thus diseases or disorders mediated by inappropriately high levels of platelet activation or platelet aggregation can be treated by administering a therapeutically effective amount of a heterocyclic compound or nonheterocyclic mitochondrial inhibitor that significantly reduces one or more platelet functions including clumping, sticking or platelet-stimulated clotting, preferably in a reversible manner.
    Type: Application
    Filed: April 25, 2011
    Publication date: December 8, 2011
    Applicant: Stanford University
    Inventors: James P. Collman, Paul Clifford Herrmann, David Alvin Tyvoll, Richard Decreau, Brian Stanley Bull, Christopher Jeffrey Barile
  • Publication number: 20110300227
    Abstract: Methods, compositions, and strategies for the treatment of malignant neoplasms are presented herein. The treatment modalities are directed towards exploiting characteristics of cancer cells as well as correcting defective biochemical pathways and systems in the body.
    Type: Application
    Filed: May 20, 2011
    Publication date: December 8, 2011
    Applicant: NORTH TEXAS MEDICAL ASSOCIATES
    Inventor: Ivan E. Danhof
  • Publication number: 20110280855
    Abstract: The field of invention relates to Vitamin C compositions, and in particular to Vitamin C compositions containing ascorbate-glucose transport enhancers. In at least one aspect, a composition is provided herein that includes ascorbate in an amount from about 0.1% by weight of actives to about 99.9% by weight of actives, and at least one ascorbate-glucose transport enhancer in an amount from about 0.01% by weight of actives to about 99.0% by weight of actives. In other aspects, methods of improving the transport of ascorbate into cells and tissues, and improving the ascorbate or antioxidant status of a person, are provided that include providing a composition comprising ascorbate and at least one ascorbate-glucose transport enhancer.
    Type: Application
    Filed: June 3, 2011
    Publication date: November 17, 2011
    Inventor: Neil Levin
  • Publication number: 20110268719
    Abstract: Annatto extract composition (AEC), including cis and trans geranyl geraniols (GG) and tocopherol-free C-5 unsubstituted tocotrienols (T3), increases the de novo synthesis of intermediate isoprenoid and distal protein products, including endogenous coenzyme Q10 (CoQ10), dolichols (DL) and all subsequent GG-prenylated and DL-glycosylated proteins, including GG-porphyrinated hemes. This intermediate and distal product replenishment by AEC reverses maladies of myotoxicity (of both drug and non-drug origins), including maladies that affect the muscle, kidney, eye, GI tract and skin, nerve, blood, and CoQ10-related syndromes of energetics and LDL protection. AEC anabolically increases the endogenous de novo CoQ10 synthesis via GG elongation/prenylation of side-chain and conversely CoQ10 catabolically increases the endogenous de novo GG synthesis via beta-oxidation of CoQ10. Also, such AEC decreases de novo synthesis and increases disposal of triglycerides (TG) in humans via PPAR activation and SREBP deactivation.
    Type: Application
    Filed: July 13, 2011
    Publication date: November 3, 2011
    Applicant: AMERICAN RIVER NUTRITION, INC.
    Inventor: Barrie TAN
  • Publication number: 20110269827
    Abstract: The invention encompasses pet food compositions and uses thereof for the treatment and/or prevention of diseases or disorders in companion animals, for example, for the treatment or prevention of degenerative joint conditions, osteoarthritis, cartilage damage, and maintaining or increasing bone mineral density, wherein the compositions and uses include feeding a companion animal a composition including uses acid or a salt thereof.
    Type: Application
    Filed: December 29, 2009
    Publication date: November 3, 2011
    Applicant: Hill's Pet Nutrition, Inc.
    Inventor: Nolan Zebulon Frantz
  • Publication number: 20110269828
    Abstract: The invention encompasses compositions and methods for treating or preventing disorders in companion animals, wherein the compositions and methods include feeding the companion animal a composition including lipoic acid or a salt thereof.
    Type: Application
    Filed: December 29, 2009
    Publication date: November 3, 2011
    Applicant: Hill's Pet Nutrition, Inc.
    Inventor: Nolan Zebulon Frantz
  • Publication number: 20110262570
    Abstract: Gene panels, microarrays and biomarker panels relating to genes and gene products associated with age-related oxidative damage to skin, and transcriptional profiling-based methods for identification and evaluation of cosmetic agents for prevention, reversal, or reduction of oxidative damage to skin. Cosmetic agents and compositions comprising the cosmetic agents, capable of inducing nrf2-mediated activation of the antioxidant response element to increase expression of Phase 2 enzymes, methods for restoring optimal redox status to skin employing the agents, and methods for identifying and evaluating cosmetic agents acting via the nrf2-mediated mechanism.
    Type: Application
    Filed: February 7, 2011
    Publication date: October 27, 2011
    Inventors: Deborah Ruth Finlay, Robert Lloyd Binder, Michael Keith Robinson, Rosemarie Osborne, Lisa Ann Mullins
  • Publication number: 20110256118
    Abstract: The invention encompasses methods for enhancing the ability of a companion animal to resist and/or overcome viral infections. The methods of the invention include an amount of lipoic acid that is effective in enhancing the antiviral immunity of a companion animal.
    Type: Application
    Filed: December 16, 2009
    Publication date: October 20, 2011
    Applicant: Hill's Pet Nutrition, Inc.
    Inventors: Jeffrey A. Brockman, Nolan Zebulon Frantz, Steven C. Zicker
  • Publication number: 20110251138
    Abstract: The present invention is a design and synthesis of a series of therapeutic conjugates which consists of tautomers of lipoic acid metabolites, with small molecule, vitamin, carbohydrates, peptides, chemotherapeutic agent wherein or not the conjugate possesses dual binding ability. The present invention can be used to therapeutics and diagnostics in vitro for cancer and other diseases associated with altered metabolic enzymes. The invention can also be used for the controlled release of more stable form of lipoic acid in its salt form with the minerals or vitamins.
    Type: Application
    Filed: June 8, 2010
    Publication date: October 13, 2011
    Inventor: Ravikumar Kabyadi Seetharama
  • Publication number: 20110251566
    Abstract: According to an illustrative embodiment a method to promote healing of a wound is provided comprising contacting the wound with a biologically active composition comprising a lipoic acid derivative and gelatin. In another embodiment a wound dressing is provided comprising a scaffold coated with a biologically active composition comprising a lipoic acid derivative. In a further embodiment, a system is provided for treating a tissue site of a patient, the system comprising a reduced-pressure source to supply reduced pressure, a manifold to distribute reduced pressure to a tissue site and a scaffold coated with a biologically active composition comprising a lipoic acid derivative. Methods for producing such a system and scaffold are also disclosed.
    Type: Application
    Filed: April 9, 2010
    Publication date: October 13, 2011
    Inventors: DMITRY ZIMNITSKY, Jenny Finkbiner